Rhinomed Ltd
ASX:RNO
Rhinomed Ltd
ASX:RNO
Price:
0.04 AUD
Market Closed
Updated:
May 21, 2024
P/E
Price to Earnings
Price to Earnings
-1
Current
-4.6
Median
23.5
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-1
Market Cap
/
11.4m
Net Income
-10.9m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| AU |
|
Rhinomed Ltd
ASX:RNO
|
11.4m AUD | -1 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 347 888.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
744.3B USD | 121.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 45.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | -15 783.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364.1B USD | 9.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
331.8B USD | 143.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.5B GBP | 37.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 16.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | -523.2 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
N/A
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A
You don't have any saved screeners yet
